2022 Refresher - Breast
Breast cancer is one of the most common malignancies treated by radiation oncologists. Indications for radiation in patients with breast cancer are increasingly dependent on advances in surgery and systemic treatments and improved understanding of tumor biology. Recent clinical trials indicate a variety of fractionation regimens involving whole breast or partial breast treatment are equally effective in patients with early stage breast cancer. This educational session will review the latest evidence supporting hypofractionated and ultrashort hypofractionated treatment regimens as well as indications for post mastectomy and regional nodal irradiation. Radiation techniques will also be discussed. Lastly, novel systemic and targeted therapies are being rapidly approved in patients with breast cancer, and this session will increase awareness regarding potential interactions between radiation and these treatments.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents, medical oncologists, surgeons, physicists, nurses, radiation therapists and dosimetrists.
Upon completion of this live activity, attendees should be able to do the following:
- Discuss a variety of equally effective radiation treatment options for patients with early stage breast cancer and determine the best option for the individual patient through shared decision making.
- Determine when and how to perform regional nodal irradiation.
- Determine the best radiation technique for delivering treatment to an individual patient.
Mylin Torres, MD is employed by Emory University School of Medicine and receives compensation from Varian, Pfizer, OncoHelath, MJHLife Sciences, Genentech and BioAscend.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.